8-K filing — Allarity Therapeutics, Inc. (ALLR)
Filed: 2026-10-01 AccNo: 0001213900-26-105457 Size: 222 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Allarity Therapeutics Expands Capabilities Of Its In-House Medical Laboratory To Include Proteomics And Cell Line Research
- Expanded laboratory capabilities support deeper mechanism-of-action research for stenoparib- New proteomics and cell line capabilities will broaden Allarity’s research capabilities to enable external
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Allarity Therapeutics Highlights DRP Technology, Patent And Lab Advances To Support Stenoparib Development And Partnerships
Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research
Allarity Therapeutics expanded its in-house medical laboratory to include proteomics and cell line research capabilities, building on existing transcriptomics and CLIA clinical testing services. The expansion aims to deepen mechanism-of-action research for stenoparib, its dual PARP and WNT pathway inhibitor, while broadening external research services. The company expects cost efficiencies without impacting current cash runway.